Psoriasis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Pediatric Psoriasis (US)

Psoriasis is a chronic, inflammatory autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management of pediatric psoriasis is more challenging owing to the limited number of treatments approved for children. Only four biologics—Amgen’s Enbrel, Janssen’s Stelara, Eli Lilly’s Taltz, and Novartis’s Cosentyx—are approved to treat pediatric and adolescent patients with psoriasis. Although topical corticosteroids continue to be the mainstay of pediatric treatment, the use of biologics is increasing, especially in the later lines, owing to the more-frequent and severe adverse events associated with long-term use of topical corticosteroids in children. Thus, there remains a significant unmet need for efficacious therapies with better safety profiles for this psoriasis subpopulation.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric psoriasis? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric psoriasis patients?
  • How have biologics such as Cosentyx, Enbrel, Humira, Remicade, Stelara, Taltz, Tremfya, and Skyrizi been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of pediatric psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of pediatric psoriasis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Markets covered: United States.

Key companies: AbbVie, Amgen, Astellas, Bausch Health, Eli Lilly, Janssen, Novartis.

Key drugs: Cosentyx, Elidel, Enbrel, Humira, Protopic, Stelara, Taclonex, Taltz, Tremfya.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Psoriasis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pediatric Psoriasis (US)
    • Treatment-Algorithms-Claims-Data-Analysis-Pediatric-Psoriasis-US-March-2022
    • Treatment Algorithms CDA Pediatric Psoriasis US 2022 Dashboard

launch Related Market Assessment Reports